Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Via Pharmaceuticals granted patent rights for inflammation compound
The patent has also been granted in New Zealand, South Africa and India and is pending in other countries. The novel compounds covered by Via’s latest patent exhibit
The patent has also been granted in New Zealand, South Africa and India and is pending in other countries. The novel compounds covered by Via’s latest patent exhibit
Last year the Indian government denied a patent for cancer treatment Gleevec on the grounds that the drug was insufficiently innovative. Under Indian law, minor improvements to major
GSK also reported the start of the first North American pre-pandemic vaccine trials in the company’s global pre-pandemic influenza program. The company has received a second task order
The Nigerian government is suing the pharmaceutical giant for roughly $8.5 billion in damages. It is also pressing criminal charges on the grounds of unethical testing of Trovan,
The drug, PF-04548043, is a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) disorders. The
Breckenridge filed an ANDA with the FDA in early 2006 and expects to receive FDA Approval and market the product in 2007. Breckenridge says it has an aggressive
The antibodies are intended as a form of passive immunization to promote clearance from the brain of the endogenous soluble Alzheimer’s toxin, beta-amyloid, where it accumulates and causes
The UK biotech said that it will recruit around 70 patients at major cancer centers in the US. The trial tests Antisoma’s anticancer aptamer AS1411 in patients with
The researchers looked at the role of the natural substance cholecystokinin (CCK) in modulating communication between cells in the brain. CCK, originally isolated from the digestive tract, is
In November 2006, Par entered into a supply and distribution agreement with AstraZeneca in the US to distribute metoprolol succinate extended release tablets, as a substitute for Toprol-XL.